Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000932471-25-000094·Crinetics Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
CRINETICS PHARMACEUTICALS INC
Common Stock · CUSIP: 22663K107
Event date: 2024-12-31
- Filing-level shares
- 9,089,391
- Percent of class
- 9.8%
- The Vanguard Group
Shares: 9,089,391 · Class: 9.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000932471-25-000094
- Form type
- SCHEDULE 13G/A
- Filer
- Crinetics Pharmaceuticals, Inc.
- CIK
- CIK 1658247
- Filed
- Jan 30, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership